Home > Gastroenterology > DDW 2024 > Cardiovascular and Metabolic Health Innovations > Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity

Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity

Presented by
Dr Soban Maan, West Virginia University, USA
Conference
DDW 2024
Doi
https://doi.org/10.55788/12811357
Bariatric surgery was compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with obesity. The primary endpoints included incident heart failure, composite cardiovascular events, and composite cerebrovascular events. The results favoured bariatric surgery.

A large-scale, retrospective study conducted between 1 January 2006 and 31 December 31 2022, included 6,790 adult patients with a BMI ≥35 [1]. Participants were divided into 2 cohorts: those who underwent bariatric surgery and those treated with GLP-1 RAs (dulaglutide, exenatide, liraglutide, semaglutide, albiglutide, and lixisenatide) for at least 2 years. To account for potential confounders, the study utilised 1:1 propensity score matching, and several sensitivity analyses were performed to ensure the robustness of the findings.

The primary endpoints were the incidence of new-onset heart failure, composite cardiovascular events, and composite cerebrovascular events. The findings indicated that bariatric surgery was associated with a lower risk of adverse cardiovascular events than GLP-1 RA therapy. Specifically, the cumulative incidence of new-onset heart failure and cardiovascular events was lower in the bariatric surgery cohort at 2, 4, and 6 years of follow-up (see Table). While the cumulative incidence of cerebrovascular events was similar between the 2 cohorts at the 2-year mark, the bariatric surgery cohort exhibited a lower risk at the 4 and 6 years of follow-up.

Table: Outcomes in patients undergoing bariatric surgery and those receiving GLP-1 RAs [1]



GLP-1 RA, glucagon-like peptide-1 receptor agonists; RR, relative risk; CI, confidence interval.

The study highlights the potential cardiovascular benefits of bariatric surgery in patients with obesity, as it was associated with a reduced risk of adverse cardiovascular events compared with GLP-1 RA therapy.


    1. Soban M, et al. Bariatric surgery versus glucagon-like peptide-1 receptor agonists: a comparison of cardiovascular outcomes. Sa1949, DDW 2024, 18–21 May, Washington DC, USA.

Copyright ©2024 Medicom Medical Publishers



Posted on